
Artificial intelligence adoption has now doubled among businesses across Britain. Government research finds 32% of companies use AI, but financial returns remain uneven and skills shortages continue to restrict wider deployment.

Scottish Widows has begun investing in four British technology companies. Its first venture-growth commitments include quantum computing specialists, a battery developer, and a healthcare technology business.

ClearRoute has released open-source software governing enterprise AI agent activity. Its alpha-stage runkora platform combines agent identity, policy-controlled access, isolated execution and audit records, with software available for engineers to inspect and test.

IntelliAM has secured conditional investment for further industrial software growth. The Sheffield company has completed subscriptions for a £6.4m financing package, including a loan-note conversion, and plans to transfer its listing from Aquis to AIM subject to shareholder approval.

Querio raises backing to improve consistency across enterprise analytics tools. The London startup has secured $5m for technology intended to give users and AI agents shared business definitions.

Sullivan and Stanley have launched conversations about business transformation delivery. The podcast began on 20 October and features executives discussing how organisations turn strategy into measurable outcomes, drawing on the consultancy’s earlier research.

Security teams gain new controls for internally developed AI applications. ThreatAware has launched Dimension, combining application building with access permissions, approvals and auditable actions.

Accounting professionals describe reservations about expanding AI within their organisations. A survey of 500 finance professionals reports concerns about information leakage, errors and workforce capability.

Private clinicians gain more flexible access to existing NHS integration. Semble says practices can activate ORB Connect for selected clinicians from 28 October and trial access until 30 November, subject to patient consent.